Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat newly diagnosed multiple myeloma ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of VRd for multiple myeloma.

Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...

Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma: Paris Saturday, July 26, 2025, 09:00 Hrs [IST] Following the positive ...

Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

After our editorial, the agency relents to allow a Duchenne treatment.

New Jersey's fiscal year budget — clocking in at $58.78 billion — advances for approval on June 30.